Advertisement

Treatment of Parkinsonism in Patients with Non-Parkinson Dementia

  • Raja Mehanna
  • Hubert H. FernandezEmail author
Chapter

Abstract

Parkinsonism and dementia can co-occur in patients without Parkinson’s disease, and most of patients with neurodegenerative parkinsonism develop significant cognitive impairment. Parkinsonism–dementia syndromes notably include dementia with Lewy bodies, progressive supranuclear palsy, corticobasal syndrome, normal-pressure hydrocephalus, vascular parkinsonism and dementia, drug-induced parkinsonism and dementia, frontotemporal lobe dementia, and Alzheimer’s disease. Therapeutic options for parkinsonism in these patients are limited, and data are scarce. In this chapter, we summarize the available information on this topic.

Keywords

Parkinsonism Dementia Treatment Dementia with Lewy bodies Progressive supranuclear palsy Corticobasal syndrome Normal-pressure hydrocephalus Frontotemporal lobe dementia Alzheimer’s disease 

References

  1. Akiguchi I, Ishii M, Watanabe Y, Watanabe T, Kawasaki T, Yagi H, Shiino A, Shirakashi Y, Kawamoto Y. Shunt-responsive parkinsonism and reversible white matter lesions in patients with idiopathic NPH. J Neurol. 2008;255(9):1392–9.PubMedCrossRefGoogle Scholar
  2. Allain H, Bentué-Ferrer D, Tribut O, Mérienne M, Belliard S. Drug therapy of frontotemporal dementia. Hum Psychopharmacol. 2003;18(3):221–5.PubMedCrossRefGoogle Scholar
  3. Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2001;13:42–9.PubMedCrossRefGoogle Scholar
  4. Birdi S, Rajput AH, Fenton M, Donat JR, Rozdilsky B, Robinson C, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002;17:1255–64.PubMedCrossRefGoogle Scholar
  5. Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology. 2004;63:376–8.PubMedCrossRefGoogle Scholar
  6. Burn DJ, Warren NM. Toward future therapies in progressive supranuclear palsy. Mov Disord. 2005;20 Suppl 12:S92–8.PubMedCrossRefGoogle Scholar
  7. Burn DJ, Rowan EN, Minett T, Sanders J, Myint P, Richardson J, et al. Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy-bodies: a cross-sectional comparative study. Mov Disord. 2003;18:884–9.PubMedCrossRefGoogle Scholar
  8. Clough CG. A case of normal pressure hydrocephalus presenting as levodopa responsive parkinsonism. J Neurol Neurosurg Psychiatry. 1987;50(2):234.PubMedCentralPubMedCrossRefGoogle Scholar
  9. Czarnecki K, Kumar N, Josephs KA. Parkinsonism and tardive antecollis in frontotemporal dementia–increased sensitivity to newer antipsychotics? Eur J Neurol. 2008;15(2):199–201.PubMedCrossRefGoogle Scholar
  10. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med. 1999;341:543–4; erratum in N Engl J Med. 1999;341:1632.PubMedCrossRefGoogle Scholar
  11. Drach LM. Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia–common features and differences. Med Monatsschr Pharm. 2011;34(2):47–52.PubMedGoogle Scholar
  12. Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord. 2008;23(3):401–4.PubMedCrossRefGoogle Scholar
  13. Fahn S, Jankovic J, Hallett M. Atypical parkinsonism, parkinsonism-plus syndromes, and secondary Parkinsonian disorders. In: Fahn S, Jankovic J, Hallett M, editors. Principles and practice of movement disorders. Philadelphia: Churchill Livingstone/Elsevier; 2011. p. 197–240.CrossRefGoogle Scholar
  14. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY. Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008;8:968–75.PubMedCrossRefGoogle Scholar
  15. Fernandez HH, Rodriguez RL, Skidmore FM, Okun MS. A practical approach to any movement disorder: diagnosis, medical and surgical management. New York: Demos Publishing, Inc; 2007.Google Scholar
  16. Frank C. Dementia with Lewy bodies. Review of diagnosis and pharmacologic management. Can Fam Physician. 2003;49:1304–11.PubMedCentralPubMedGoogle Scholar
  17. Giménez-Roldán S, Mateo D, Escalona-Zapata J. Familial Alzheimer’s disease presenting as levodopa-responsive parkinsonism. Adv Neurol. 1987;45:431–6.PubMedGoogle Scholar
  18. Golbe LI, Sage JI, Duvoisin RC. Drug treatment of 83 patients with progressive supranuclear palsy. Neurology. 1990;40:438.Google Scholar
  19. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23(15):2248–50.PubMedCrossRefGoogle Scholar
  20. Graff-Radford NR, Woodruff BK. Frontotemporal dementia. Semin Neurol. 2007;27(1):48–57.PubMedCrossRefGoogle Scholar
  21. Imamura T, Takanashi M, Hattori N, et al. Bromocriptine treatment for perseveration in demented patients. Alzheimer Dis Assoc Disord. 1998;12:109–13.PubMedCrossRefGoogle Scholar
  22. Irene L, Yves A, editors. Progressive supranuclear palsy: clinical and research approaches. New York: Oxford University Press; 1992.Google Scholar
  23. Jankovic J, Newmark M, Peter P. Parkinsonism and acquired hydrocephalus. Mov Disord. 1986;1:59–64.PubMedCrossRefGoogle Scholar
  24. Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998a;55(8):1099–102.PubMedCrossRefGoogle Scholar
  25. Kompoliti K, Goetz CG, Boeve BF, Maraganore DM, Ahlskog JE, Marsden CD, et al. Clinical presentation and pharmacologic therapy in corticobasal degeneration. Arch Neurol. 1998b;55:957–61.PubMedCrossRefGoogle Scholar
  26. Kurlan R, Richard IH, Papka M, Marshall F. Movement disorders in Alzheimer's disease: more rigidity of definitions needed. Mov Disord. 2000;15:24–9.PubMedCrossRefGoogle Scholar
  27. Liepelt-Scarfone I, Jamour M, Maetzler W. Co-occurrence of parkinsonism and dementia in clinical practice: relevant differential diagnoses. Z Gerontol Geriatr. 2012;45(1):23–33.PubMedCrossRefGoogle Scholar
  28. Lim T, Ahmed A, Itin I, Gostkowski M, Rudolph J, Cooper S, Fernandez HH. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson’s disease? Int J Neurosci. 2013;123(3):170–4.PubMedCrossRefGoogle Scholar
  29. Lubarsky M, Juncos JL. Progressive supranuclear palsy: a current review. Neurologist. 2008;14(2):79–88.PubMedCrossRefGoogle Scholar
  30. Lucetti C, Logi C, Del Dotto P, Berti C, Ceravolo R, Baldacci F, Dolciotti C, Gambaccini G, Rossi G, Bonuccelli U. Levodopa response in dementia with Lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010;16(8):522–6.PubMedCrossRefGoogle Scholar
  31. Mehanna R, Jankovic J. Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord. 2010;16(10):628–38.PubMedCrossRefGoogle Scholar
  32. Mehanna R, Jankovic J. Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci. 2013a;328(1–2):1–8.PubMedCrossRefGoogle Scholar
  33. Mehanna R, Jankovic J. Movement disorders in cerebrovascular disease. Lancet Neurol. 2013b;12(6):597–608.PubMedCrossRefGoogle Scholar
  34. Morishita T, Foote KD, Okun MS. INPH and Parkinson disease: differentiation by levodopa response. Nat Rev Neurol. 2010;6(1):52–6.PubMedCrossRefGoogle Scholar
  35. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113–24.PubMedCrossRefGoogle Scholar
  36. McKeith IG, Burn DJ, Ballard CG, Collerton D, Jaros E, Morris CM, et al. Dementia with Lewy bodies. Semin Clin Neuropsychiatry. 2003;8(1):46–57.PubMedCrossRefGoogle Scholar
  37. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al., Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72.Google Scholar
  38. Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76(9):1200–3.PubMedCentralPubMedCrossRefGoogle Scholar
  39. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Effects of selegiline on frontotemporal dementia: a neuropsychological evaluation. Int J Geriatr Psychiatry. 2002;17:391–2.PubMedCrossRefGoogle Scholar
  40. Murata M, Hasegawa K, Kanazawa I, The Japanese Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, doubleblind study. Neurology. 2007;68:45–50.PubMedCrossRefGoogle Scholar
  41. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993;16:338–46.PubMedCrossRefGoogle Scholar
  42. Odawara T, Shiozaki K, Togo T, Hirayasu Y. Administration of zonisamide in three cases of dementia with Lewy bodies. Psychiatry Clin Neurosci. 2010;64(3):327–9.PubMedCrossRefGoogle Scholar
  43. Papapetropoulos S, Lieberman A, Gonzalez J, Singer C, Laufer DZ, Mash DC. Family history of dementia: dementia with Lewy bodies and dementia in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2006;18(1):113–6.PubMedCrossRefGoogle Scholar
  44. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease. A randomized controlled trial. JAMA. 2000;84:1931–8.CrossRefGoogle Scholar
  45. Possin KL, Kaufer DI. Parkinsonian dementias. Continuum. 2010;16(2 Dementia):57–79.PubMedGoogle Scholar
  46. Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord. 2005;20 Suppl 12:S77–82.PubMedCrossRefGoogle Scholar
  47. Pujari S, Kharkar S, Metellus P, Shuck J, Williams MA, Rigamonti D. Normal pressure hydrocephalus: long-term outcome after shunt surgery. J Neurol Neurosurg Psychiatry. 2008;79(11):1282–6.PubMedCrossRefGoogle Scholar
  48. Racette BA, Esper GJ, Antenor J, Black KJ, Burkey A, Moerlein SM, et al. Pathophysiology of parkinsonism due to hydrocephalus. J Neurol Neurosurg Psychiatry. 2004;75:1617–9.PubMedCentralPubMedCrossRefGoogle Scholar
  49. Rahman S, Robbins TW, Sahakian BJ. Comparative cognitive neuropsychological studies of frontal lobe function: implications for therapeutic strategies in frontal variant frontotemporal dementia. Dement Geriatr Cogn Disord. 2001;10 Suppl 1:15–28.CrossRefGoogle Scholar
  50. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;18(342):1481–91.Google Scholar
  51. Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24(5):375–98.PubMedCentralPubMedCrossRefGoogle Scholar
  52. Reed LA, Wszolek ZK, Hutton M. Phenotypic correlations in FTDP-17. Neurobiol Aging. 2001;22:89–107.PubMedCrossRefGoogle Scholar
  53. Sato S, Mizukami K, Asada T. Successful treatment of extrapyramidal and psychotic symptoms with zonisamide in a patient with dementia with Lewy bodies. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):1130–1.PubMedCrossRefGoogle Scholar
  54. Serrano-Duenas M. Neuroleptic malignant syndrome-like, or—dopaminergic malignant syndrome—due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord. 2003;9:175–8.PubMedCrossRefGoogle Scholar
  55. van Balken I, Litvan I. Current and future treatments in progressive supranuclear palsy. Curr Treat Options Neurol. 2006;8:211–23.PubMedCrossRefGoogle Scholar
  56. Vanneste JA. Diagnosis and management of normal-pressure hydrocephalus. J Neurol. 2000;247:5–14.PubMedCrossRefGoogle Scholar
  57. Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Parkinsonian like signs and risk of incident Alzheimer disease in older persons. Arch Neurol. 2003;60:539–44.PubMedCrossRefGoogle Scholar
  58. Wurtman RJ. Personalized medicine strategies for managing patients with parkinsonism and cognitive deficits. Metabolism. 2013;62 Suppl 1:S27–9.PubMedCrossRefGoogle Scholar
  59. Wszolek ZK, Tsuboi Y, Ghetti B, Pickering-Brown S, Baba Y, Cheshire WP. Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Orphanet J Rare Dis. 2006;1:30.PubMedCentralPubMedCrossRefGoogle Scholar
  60. Yoshikawa H, Oda Y, Sakajiri K, Takamori M, Nakanishi I, Makifuchi T, et al. Pure akinesia manifested neuroleptic malignant syndrome: a clinical variant of progressive Supranuclear palsy. Acta Neuropathol. 1997;93:306–9.PubMedCrossRefGoogle Scholar
  61. Zeidler M, Dorman PJ, Ferguson IT, Bateman DE. Parkinsonism associated with obstructive hydrocephalus due to idiopathic aqueductal stenosis. J Neurol Neurosurg Psychiatry. 1998;64(5):657–9.PubMedCentralPubMedCrossRefGoogle Scholar
  62. Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13(5). pii: PCC.11r01190. doi:  10.4088/PCC.11r01190. PMID:22295275.

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Texas Health Science Center in HoustonHoustonUSA
  2. 2.Department of NeurologyCleveland Clinic Lerner College of MedicineClevelandUSA

Personalised recommendations